Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval

  |  Issue: April 2018  |  

Benzhydrocodone is a prodrug of hydrocodone developed using proprietary Ligand Activated Therapy. When Apadaz is ingested, gastrointestinal tract enzymes cleave the ligand from benzhydrocodone, releasing hydrocodone, to work therapeutically.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Food and Drug Administration. FDA drug safety communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease. 2018 Feb 22.
  2. KemPharm Inc. News release: KemPharm announces FDA approval of Apadaz (benzhydrocodone and acetaminophen) for the short-term management of acute pain. 2018 Feb 23.

Related Articles

    Psoriatic Arthritis Drugs at a Glance, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

    Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination

    FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising…